Drug interactions for elderly with respiratory disorders and times of COVID-19: a systematic scoping review


  • Marcela Forgerini São Paulo State University (UNESP)
  • Geovana Schiavo São Paulo State University (UNESP)
  • Rosa Camila Lucchetta São Paulo State University (UNESP)
  • Patricia Mastroianni São Paulo State University (UNESP) https://orcid.org/0000-0001-8467-7278




Coronavirus Infections, Contraindications Drug, Drug-Related Effects and Adverse Reactions, Inappropriate Prescribing, Older Adults, Potentially Inappropriate Medication List, Patient Safety, Respiratory Tract Diseases


Background: The elderly people have high morbimortality associated with respiratory disorders, in addition to the presence of other safety risk factors, such as the use of potentially inappropriate medication and the occurrence of drug interactions. Objective: Considering the current pandemic scenario, it was intended to identify explicit criteria-based tools that reported drug interactions between potentially inappropriate medication and respiratory system disorders and possibly worse prognosis of COVID-19 infection. Methods: A systematic scoping review was conducted until February 2020. Study characteristics of explicit criteria-based tools, and potentially inappropriate medication, drug interactions, and therapeutic management, were extracted. Results: Nineteen explicit criteria-based tools were included. Nineteen drug interactions and 17 potentially inappropriate medications with concerns for three respiratory disorders (asthma, chronic pulmonary obstructive disease, and respiratory failure) were identified. The most frequent pharmacological classes reported were benzodiazepines and beta-blockers. For clinical management, the tools recommend using cardioselective beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type I receptor blockers, and benzodiazepines with a short or intermediate half-life. Conclusion: Considering the increased risk of COVID-19 infection in the elderly, drug interactions and the use of potentially inappropriate medication associated with the occurrence of adverse drug events in the respiratory system may also worsening COVID-19 infection in patients with uncontrolled respiratory disorders. Thus, it is essential to assess drug therapy in use, to identify safety risks, and monitor the elderly in general and those with a worse prognosis concerning COVID-19, promoting patient safety.

= 753 veces | PDF
= 462 veces|


Download data is not yet available.

Author Biographies

Marcela Forgerini, São Paulo State University (UNESP)

PhD Student. Department of Drugs and Medicines, School of Pharmaceutical Sciences

Geovana Schiavo, São Paulo State University (UNESP)

Graduate Student. Department of Drugs and Medicines, School of Pharmaceutical Sciences,

Rosa Camila Lucchetta, São Paulo State University (UNESP)

PhD. Department of Drugs and Medicines, School of Pharmaceutical Sciences,

Patricia Mastroianni, São Paulo State University (UNESP)

PhD. Associate Professor. Department of Drugs and Medicines, Faculty of Pharmaceutical Sciences,


Angus DC. Current and Projected Workforce Requirements for Care of the Critically Ill and Patients With Pulmonary Disease. JAMA. 2000 Dec 6;284(21):2762. DOI: https://doi.org/10.1001/jama.284.21.2762

Thanaviratananich S, Cho S-H, Ghoshal AG, Muttalif ARBA, Lin H-C, Pothirat C, et al. Burden of respiratory disease in Thailand: Results from the APBORD observational study. Medicine (Baltimore). 2016 Jul;95(28):e4090. DOI: https://doi.org/10.1097/MD.0000000000004090

Wang DY, Ghoshal AG, Bin Abdul Muttalif AR, Lin H-C, Thanaviratananich S, Bagga S, et al. Quality of Life and Economic Burden of Respiratory Disease in Asia-Pacific—Asia-Pacific Burden of Respiratory Diseases Study. Value Heal Reg Issues. 2016 May;9:72–7. DOI: https://doi.org/10.1016/j.vhri.2015.11.004

Carreiro-Martins P, Gomes-Belo J, Papoila AL, Caires I, Palmeiro T, Gaspar-Marques J, et al. Chronic respiratory diseases and quality of life in elderly nursing home residents. Chron Respir Dis. 2016 Aug;13(3):211–9. DOI: https://doi.org/10.1177/1479972316636990

Shahid Z, Kalayanamitra R, McClafferty B, Kepko D, Ramgobin D, Patel R, et al. COVID‐19 and Older Adults: What We Know. J Am Geriatr Soc [Internet]. 2020 May 20;68(5):926–9. DOI: https://doi.org/10.1111/jgs.16472

Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91–5. DOI: https://doi.org/10.1016/j.ijid.2020.03.017

von der Thüsen J, Eerden M. Histopathology and genetic susceptibility in COVID‐19 pneumonia. Eur J Clin Invest. 2020 Jul 27;50(7):eci.13259. DOI: https://doi.org/10.1111/eci.13259

Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020 Apr 28;323(16):1612. DOI: https://doi.org/10.1001/jama.2020.4326

Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Northfield Il). 2020 Mar;20(2):124–7. DOI: https://doi.org/10.7861/clinmed.2019-coron

Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacol Res. 2020 Aug;158:104906. DOI: https://doi.org/10.1016/j.phrs.2020.104906

O Riordan D, Aubert CE, Walsh KA, Van Dorland A, Rodondi N, Du Puy RS, et al. Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional study. BMJ Open. 2018 Mar 22;8(3):e019003. DOI: https://doi.org/10.1136/bmjopen-2017-019003

Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc. 2009 Mar;57(3):560–1. DOI: https://doi.org/10.1111/j.1532-5415.2009.02131.x.

Forgerini M, Herdeiro MT, Galduróz JCF, Mastroianni P de C. Sao Paulo Med J. 2020 Jun;138(3):216–8. Risk factors associated with drug therapy among elderly people with Alzheimer’s disease: a cross-sectional study. DOI: https://doi.org/10.1590/1516-3180.2019.0461.r2.19022020

Varallo FR, Costa MA, Mastroianni P de C. Potenciais interações medicamentosas responsáveis por internações hospitalares. Rev Ciencias Farm Basica e Apl. 2013;

Mastroianni P de C, Forgerini M. Compliance and Drug Related Problems in probable Alzheimer’s disease elderly. Int Psychogeriatrics. 2019;1–2. DOI: https://doi.org/10.1017/S104161021800234X

Komagamine J. Prevalence of potentially inappropriate medications at admission and discharge among hospitalised elderly patients with acute medical illness at a single centre in Japan: a retrospective cross-sectional study. BMJ Open. 2018 Jul 19;8(7):e021152. DOI: https://doi.org/10.1136/bmjopen-2017-021152

Almeida; LS de, Nascimento; MMG do, Oliveira; DR de, Oliveira; I V., Detoni; LB, Caux; TR de, et al. Potentially inappropriate medication use profile among older people with chronic obstructive pulmonary disease. Rev Ciências da Saúde Básica e Apl. 2019;2:29–42.

Forgerini M, Schiavo G, Lucchetta RC, Mastroianni P de C. Drug interactions for elderly people with mental and behavioral disorders: a systematic scoping review. Arch Gerontol Geriatr. 2020; DOI: https://doi.org/10.1016/j.archger.2020.104283

The Joanna Briggs Institute. Summary for Policymakers. In: Intergovernmental Panel on Climate Change, editor. Climate Change 2013 - The Physical Science Basis. Cambridge: Cambridge University Press; 2015. p. 1–30.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). [Internet]. 2019. Available from: https://training.cochrane.org/handbook

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018 Oct 2;169(7):467.

Schiavo G, Lucchetta RC, Forgerini M, Mastroianni P de C. Assessment tool for potentially inappropriate medication use in the elderly: a scoping review protocol. Rev Ciências Farm Básica e Apl. 2018;39:e637.

Lucchetta R. Potentially inappropriate medications criteria-based tools for the elderly: a systematic scoping review. OSF. 2020; DOI: https://doi.org/10.17605/OSF.IO/EUVR2

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21. DOI: https://doi.org/10.1016/S2213-2600(20)30116-8

Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May;55(5):2000547. DOI: https://doi.org/10.1183/13993003.00547-2020

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar;395(10229):1054–62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Apr;525(1):135–40. DOI: https://doi.org/10.1016/j.bbrc.2020.02.071

Williams B, Zhang Y. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. Lancet. 2020 May;395(10238):1671–3. DOI: https://doi.org/10.1016/S0140-6736(20)31131-4

Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 May 1;NEJMoa2008975. DOI: https://doi.org/10.1056/NEJMoa2008975

Bean; DM, Kraljevic; Zeljko, Searle; T, Bendayan; R, Pickles1; A, Folarin; A, et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. medRxiv. 2020; DOI: https://doi.org/10.1101/2020.04.07.20056788

de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020 May;395(10238):1705–14. DOI: https://doi.org/10.1016/S0140-6736(20)31030-8

Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19; DOI: https://doi.org/10.1002/14651858.CD003566.pub2

Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse Respiratory Effect of Acute β-Blocker Exposure in Asthma. Chest. 2014 Apr;145(4):779–86. DOI: https://doi.org/10.1378/chest.13-1235

Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, et al. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respir Res. 2017 Dec 19;18(1):124. DOI: https://doi.org/10.1186/s12931-017-0609-7

Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017 Dec 27;15(1):18. DOI: https://doi.org/10.1186/s12916-017-0781-0

Hernandez A V., Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med. 2020 May;M20-2496. DOI: https://doi.org/10.7326/M20-2496

Patel TK, Barvaliya M, Kevadiya BD, Patel PB, Bhalla HL. Does Adding of Hydroxychloroquine to the Standard Care Provide Any Benefit in Reducing the Mortality Among COVID-19 Patients?: A Systematic Review. J Neuroimmune Pharmacol. 2020; DOI: https://doi.org/10.1007/s11481-020-09930-x

Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015 Jun 1;70(6):1608–21. DOI: https://doi.org/10.1093/jac/dkv018

Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Can Med Assoc J [Internet]. 2020 Apr 27;192(17):E450–3. Available from: http://www.cmaj.ca/lookup/doi/10.1503/cmaj.200528

Mascolo A, Berrino PM, Gareri P, Castagna A, Capuano A, Manzo C, et al. Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. Inflammopharmacology. 2018 Oct 9;26(5):1141–9. DOI: https://doi.org/10.1007/s10787-018-0498-5

Ross SB, Wilson MG, Papillon‐Ferland L, Elsayed S, Wu PE, Battu K, et al. COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. J Am Geriatr Soc. 2020 Aug 30;68(8):1636–46. DOI: https://doi.org/10.1111/jgs.16623

Kroll DS, Nieva HR, Barsky AJ, Linder JA. Benzodiazepines are Prescribed More Frequently to Patients Already at Risk for Benzodiazepine-Related Adverse Events in Primary Care. J Gen Intern Med. 2016 Sep 13;31(9):1027–34. DOI: https://doi.org/10.1007/s11606-016-3740-0

Baillargeon J, Singh G, Kuo Y-F, Raji MA, Westra J, Sharma G. Association of Opioid and Benzodiazepine Use with Adverse Respiratory Events in Older Adults with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2019 Oct;16(10):1245–51. DOI: https://doi.org/10.1513/AnnalsATS.201901-024OC.

Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR. Association between benzodiazepine use and exacerbations and mortality in patients with asthma: a matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):793–802. DOI: https://doi.org/10.1002/pds.3799

Lucchetta RC, da Mata BPM, Mastroianni P de C. Association between Development of Dementia and Use of Benzodiazepines: A Systematic Review and Meta-Analysis. Pharmacother J Hum Pharmacol Drug Ther. 2018 Oct;38(10):1010–20. DOI: https://doi.org/10.1002/phar.2170

Scichilone N. Comorbidities of Lung Disease in the Elderly. Clinics in Geriatric Medicine. 2017. DOI: https://doi.org/10.1016/j.cger.2017.06.010.

Leal LF, Bertoldi AD, Menezes AMB, Borges RB, Mengue SS, Gazzana MB, et al. Indicação, acesso e utilização de medicamentos para doenças respiratórias crônicas no Brasil: resultados da Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos no Brasil (PNAUM), 2014. Cad Saude Publica. 2018 Oct 11;34(10). DOI: https://doi.org/10.1590/0102-311x00208217

Scichilone N, Ventura MT, Bonini M, Braido F, Bucca C, Caminati M, et al. Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy. 2015 Dec 22;13(1):7. DOI: https://doi.org/10.1186/s12948-015-0016-x

Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013 Oct;107(10):1481–90. DOI: https://doi.org/10.1016/j.rmed.2013.04.005

Muir J-F, Lamia B, Molano C, Cuvelier A. Respiratory Failure in the Elderly Patient. Semin Respir Crit Care Med. 2010 Oct 12;31(05):634–46. DOI: https://doi.org/10.1055/s-0030-1265903.

Shoemaker SJ, Ramalho de Oliveira D. Understanding the meaning of medications for patients: The medication experience. Pharm World Sci. 2007 Nov 21;30(1):86–91. DOI: https://doi.org/10.1007/s11096-007-9148-5

O’Mahony D, Gallagher P, Lavan A. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016 Jun;11:857. DOI: https://doi.org/10.2147/CIA.S80280

Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing Medications for Chronic Diseases Management in Primary Care Settings: A Systematic Review of Randomized Controlled Tri

als. J Am Med Dir Assoc. 2018 Nov;19(11):923-935.e2. DOI: https://doi.org/10.1016/j.jamda.2018.06.021

Gabe ME, Murphy F, Davies GA, Russell IT, Jordan S. Medication Monitoring in a Nurse-Led Respiratory Outpatient Clinic: Pragmatic Randomised Trial of the West Wales Adverse Drug Reaction Profile. Scheurer M, editor. PLoS One. 2014 May 5;9(5):e96682. DOI: https://doi.org/10.1371/journal.pone.0096682

Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Arch Intern Med. 2003 Dec 8;163(22):2716. DOI: https://doi.org/10.1001/archinte.163.22.2716

Winit-Watjana W, Sakulrat P, Kespichayawattana J. Criteria for high-risk medication use in Thai older patients. Arch Gerontol Geriatr. 2008 Jul;47(1):35–51. DOI: https://doi.org/10.1016/j.archger.2007.06.006

Kim DS, Heo SI, Lee SH. Development of a List of Potentially Inappropriate Drugs for the Korean Elderly Using the Delphi Method. Healthc Inform Res. 2010;16(4):231. DOI: https://doi.org/10.4258/hir.2010.16.4.231

Mimica Matanović S, Vlahovic-Palcevski V. Potentially inappropriate medications in the elderly: a comprehensive protocol. Eur J Clin Pharmacol. 2012 Aug 24;68(8):1123–38. DOI: https://doi.org/10.1007/s00228-012-1238-1

Mann E, Böhmdorfer B, Frühwald T, Roller-Wirnsberger RE, Dovjak P, Dückelmann-Hofer C, et al. Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr. 2012 Mar 2;124(5–6):160–9. DOI: https://doi.org/10.1007/s00508-011-0061-5

Fialová D. Potentially Inappropriate Medication Use Among Elderly Home Care Patients in Europe. JAMA. 2005 Mar 16;293(11):1348. DOI: https://doi.org/10.1001/jama.293.11.1348.

Clyne B, Bradley MC, Hughes CM, Clear D, McDonnell R, Williams D, et al. Addressing potentially inappropriate prescribing in older patients: development and pilot study of an intervention in primary care (the OPTI-SCRIPT study). BMC Health Serv Res. 2013 Dec 14;13(1):307. DOI: https://doi.org/10.1186/1472-6963-13-307

Delgado Silveira E, Montero Errasquín B, Muñoz García M, Vélez-Díaz-Pallarés M, Lozano Montoya I, Sánchez-Castellano C, et al. Mejorando la prescripción de medicamentos en las personas mayores: una nueva edición de los criterios STOPP-START. Rev Esp Geriatr Gerontol. 2015 Mar;50(2):89–96. DOI: https://doi.org/10.1016/j.regg.2014.10.005

O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014 Oct 16;44(2):213–8. DOI: https://doi.org/10.1093/ageing/afu145

Tommelein E, Petrovic M, Somers A, Mehuys E, van der Cammen T, Boussery K. Older patients’ prescriptions screening in the community pharmacy: development of the Ghent Older People’s Prescriptions community Pharmacy Screening (GheOP3S) tool. J Public Health (Bangkok). 2016 Jun;38(2):e158–70. DOI: https://doi.org/10.1093/pubmed/fdv090

Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015 Jul 14;71(7):861–75. DOI: https://doi.org/10.1007/s00228-015-1860-9

Kojima T, Mizukami K, Tomita N, Arai H, Ohrui T, Eto M, et al. Screening Tool for Older Persons’ Appropriate Prescriptions for Japanese: Report of the Japan Geriatrics Society Working Group on “Guidelines for medical treatment and its safety in the elderly.” Geriatr Gerontol Int. 2016 Sep;16(9):983–1001. DOI: https://doi.org/10.1111/ggi.12890

Poudel A, Ballokova A, Hubbard RE, Gray LC, Mitchell CA, Nissen LM, et al. Algorithm of medication review in frail older people: Focus on minimizing the use of high-risk medications. Geriatr Gerontol Int. 2016 Sep;16(9):1002–13. DOI: https://doi.org/10.1111/ggi.12589

Oliveira MG, Amorim WW, Oliveira CRB, Coqueiro HL, Gusmão LC, Passos LC. Consenso brasileiro de medicamentos potencialmente inapropriados para idosos. Geriatr Gerontol Aging. 2017 Dec;10(4):168–81. DOI: https://doi.org/10.5327/Z2447-211520161600054

Kim M-Y, Etherton-Beer C, Kim C-B, Yoon JL, Ga H, Kim HC, et al. Development of a Consensus List of Potentially Inappropriate Medications for Korean Older Adults. Ann Geriatr Med Res. 2018 Sep 30;22(3):121–9. DOI: https://doi.org/10.4235/agmr.2018.22.3.121

Marzi MM, Pires MS, Quaglia NB. Ingredientes Farmacéuticos Activos Potencialmente Inapropiados en Adultos Mayores: Lista IFAsPIAM: Panel de Consenso Argentino. Value Heal Reg Issues. 2018; DOI: https://doi.org/10.1016/j.vhri.2017.10.002

Samaranayake NR, Balasuriya A, Fernando GH, Samaraweera D, Shanika LGT, Wanigasuriya JKP, et al. ‘Modified STOPP-START criteria for Sri Lanka’; translating to a resource limited healthcare setting by Delphi consensus. BMC Geriatr. 2019 Dec 22;19(1):282. DOI: https://doi.org/10.1186/s12877-019-1293-x

Gonzalez-Colaço Harmand M, Aldea-Perona AM, Boada-Fernández del Campo C, Areosa-Sastre A, Rodríguez-Jiménez C, García Sánchez-Colomer M, et al. Spanish list of potentially inappropriate drugs in the elderly (ES-PIA project). Eur J Clin Pharmacol. 2019 Aug 8;75(8):1161–76. DOI: https://doi.org/10.1007/s00228-019-02684-3

Chang C-B, Lai H-Y, Hwang S-J, Yang S-Y, Wu R-S, Chang L-Y, et al. The updated PIM-Taiwan criteria: a list of potentially inappropriate medications in older people. Ther Adv Chronic Dis. 2019 Jan 5;10:204062231987960. DOI: https://doi.org/10.1177/2040622319879602




How to Cite

Forgerini, M., Schiavo, G., Lucchetta, R. C., & Mastroianni, P. (2020). Drug interactions for elderly with respiratory disorders and times of COVID-19: a systematic scoping review. Vitae, 27(3). https://doi.org/10.17533/udea.vitae.v27n3a02




Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.